Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Murakami, Masahiro ^a,b   Nishina, Kazutaka ^b,c   Watanabe, Chie ^a,b   Yoshida Tanaka, Kie ^b,c   Piao, Wenying ^b,c   Kuwahara, Hiroya ^b,c   Horikiri, Yuji ^a   Miyata, Kanjiro ^d   Nishiyama, Nobuhiro ^d,e   Kataoka, Kazunori ^d,f   Yoshida, Masayuki ^c   Mizusawa, Hidehiro ^c,g   Yokota, Takanori ^b,c  

^a OSAKA OHTANI UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; CHYLOMICRON; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; ORGANOPHOSPHORUS COMPOUND; PHOSPHORAMIDOUS ACID; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE SILENCING; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; JEJUNUM; LIVER; LYMPH VESSEL; METABOLISM; MOUSE; PHYSIOLOGY; POSTPRANDIAL STATE; PROCEDURES; RECTAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, RECTAL; ALPHA-TOCOPHEROL; ANIMALS; APOLIPOPROTEINS B; BIOLOGICAL TRANSPORT; CHYLOMICRONS; DRUG DELIVERY SYSTEMS; GENE SILENCING; JEJUNUM; LIPOPROTEINS, LDL; LIVER; LYMPHATIC VESSELS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NANOPARTICLES; ORGANOPHOSPHORUS COMPOUNDS; POSTPRANDIAL PERIOD; RNA, SMALL INTERFERING;

EID: 84947997998     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17035     Document Type: Article

References (34)

1. Soutschek, J., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
2. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711-719 (2006).
3. Rettig, G. R. & Behlke, M. A. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20, 483-512 (2011).
4. Kappus, H. & Diplock, A. T. Tolerance and safety of vitamin E: a toxicological position report. Free Radic. Biol. Med. 13, 55-74 (1992).
5. Nishina, K., et al. Efficient in vivo delivery of siRNA to the liver by conjugation of α-Docopherol. Mol. Ther. 16, 734-740 (2008).
6. Wolfrum, C., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157 (2007).
7. Williams, K. J. Molecular processes that handle-And mishandle-dietary lipids. J. Clin. Invest. 118, 3247-3259 (2008).
8. Waters, D. D., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120, 28-34 (2009).
9. Cholesterol Treatment Trialists? (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170, 000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
10. Aouadi, M., et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458, 1180-1184 (2009).
11. Will, D. W. & Brown, T. Attachment of vitamin E derivatives to oligonucleotides duringsolid-phase synthesis. Tetrahedron Lett. 33, 2729-2732 (1992).
12. Willnow, T. E. Mechanisms of hepatic chylomicron remnant clearance. Diabet. Med. 14, S75-S80 (1997)
13. Abe, C., et al. Triton WR1339, an inhibitor of lipoprotein lipase, decreases vitamin E concentration in some tissues of rats by inhibiting its transport to liver. J. Nutr. 137, 345-350 (2007).
14. Bu, G. The roles of receptor-Associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int. Rev. Cytol. 209, 79-116 (2001).
15. Xiang, T. X. & Anderson, B. D. Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys. J. 75, 2658-2671 (1998).
16. Erin, A. N., Spirin, M. M., Tabidze, L. V. & Kagan, V. E. Formation of alpha-Docopherol complexes with fatty acids. A hypothetical mechanism of stabilization of biomembranes by vitamin E. Biochim. Biophys. Acta 774, 96-102 (1984).
17. Muranishi, S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7, 1-33 (1990).
18. Deli, M. A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 1788, 892-910 (2007).
19. Snipes, R. L. Limited fat absorption in the large intestine of mice. A morphological study. Acta Anat. 99, 435-459 (1977).
20. Citi, S., et al. Cingulin, a new peripheral component of tight junctions. Nature 333, 272-276 (1988).
21. Karlsson, R. & Lindberg, U. Changes in the organization of actin and myosin in non-muscle cells induced by N-ethylmaleimide. Exp. Cell Res. 157, 95-115 (1985).
22. Murakami, M., Takada, K. & Muranishi, S. Further mechanistic study on intestinal absorption enhanced by unsaturated fatty acids: reversible effect by sulfhydryl modification. Biochim. Biophys. Acta 1117, 83-89 (1992).
23. Craven, P. A. & DeRubertis, F. R. Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation by unsaturated fatty acids. Gastroenterology 95, 676-685 (1988).
24. Yoshikawa, H., Takada, K. & Muranishi, S. Molecular weight dependence of permselectivity to rat small intestinal blood-lymph barrier for exogenous macromolecules absorbed from lumen. J. Pharmacobiodyn. 7, 1-6 (1984).
25. Yoshikawa, H., Takada, K. & Muranishi, S. Molecular weight-dependent lymphatic transfer of exogenous macromolecules from large intestine of renal insufficiency rats. Pharm. Res. 9, 1195-1198 (1992).
26. Tso, P., Pitts, V. & Granger, D. N. Role of lymph flow in intestinal chylomicron transport. Am. J. Physiol. 249, G21-G28 (1985).
27. Love, K. T., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA 107, 1864-1869 (2010).
28. Pack, D. W., Hoffman, A. S., Pun, S. & Stayton, P. S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4, 581-593 (2005).
29. Miyata, K., Nishiyama, N. & Kataoka, K. Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. Chem. Soc. Rev. 41, 2562-2574 (2012).
30. Nair, J. K., et al. Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961 (2014).
31. Matsuda, S., et al. siRNA conjugates carrying sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181-1187 (2015).
32. Prakash, T. P., et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-Acetyl galactosamine improves potency 10-fold in mice. Nucleic. Acids. Res. 42, 8796-8807 (2014).
33. Nishina, T., et al. Chimeric antisense oligonucleotide conjugated to α-Docopherol. Mol. Ther. Nucleic Acids. 4, e220 (2015).
34. Nishina, K., et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6, 7969 (2015).